

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

BOSTON SCIENTIFIC CORPORATION and)	
BOSTON SCIENTIFIC SCIMED, INC.,)	
)	
Plaintiffs,)	Civil Action No. 07-333-SLR
)	
v.)	
)	JURY TRIAL DEMANDED
JOHNSON & JOHNSON, INC. and)	
CORDIS CORPORATION,)	
)	
Defendants.)	
)	

ANSWER AND COUNTERCLAIMS

Johnson & Johnson, Inc. (“J&J”) and Cordis Corporation (“Cordis Corp.”) (collectively, “Cordis”), by their attorneys, for their Answer to the Complaint for Declaratory Judgment of Patent Invalidity and Noninfringement (“Complaint”) of Boston Scientific Corporation and Boston Scientific Scimed, Inc. (collectively, “Plaintiffs”), hereby state as follows:

COMPLAINT 1. This is an action for a declaratory judgment that United States Patent No. 7,217,286 entitled “Local Delivery of Rapamycin for Treatment of Proliferative Sequelae Associated With PTCA Procedures, Including Delivery Using a Modified Stent” (“the Falotico ‘286 patent”) is invalid and not infringed by BSC. The Falotico ‘286 patent is attached as Exhibit A.

ANSWER 1. Cordis admits that Boston Scientific’s Complaint purports to state a claim for a declaratory judgment that U.S. Patent No. 7,217,286 (“the ‘286 patent”) is invalid and not infringed. Cordis also admits that a copy of the ‘286 patent was attached to Boston Scientific’s Complaint. Cordis otherwise denies the allegations in Paragraph 1.

COMPLAINT 2. Plaintiff Boston Scientific Corporation is a corporation organized under the laws of the State of Delaware, having its principal place of business at One Boston Scientific Plaza, Natick, Massachusetts 01760.

ANSWER 2. Cordis admits the allegations in Paragraph 2.

COMPLAINT 3. Plaintiff Boston Scientific Scimed, Inc. is a corporation organized under the laws of the State of Minneapolis, having its principal place of business at One Scimed Place, Maple Grove, MN 55311-1566.

ANSWER 3. Cordis admits the allegations in Paragraph 3.

COMPLAINT 4. Upon information and belief, Defendant Johnson & Johnson, Inc. is a corporation organized under the laws of the State of New Jersey and has a principal place of business at 1 Johnson and Johnson Plaza, New Brunswick, New Jersey.

ANSWER 4. Cordis admits the allegations in Paragraph 4.

COMPLAINT 5. Upon information and belief, Defendant Cordis Corporation (“Cordis”) is a corporation organized under the laws of the State of Florida and has a principal place of business in Miami Lakes, Florida. Cordis is a subsidiary of Johnson & Johnson, Inc.

ANSWER 5. Cordis admits that Cordis Corp. is a corporation organized under the laws of the State of Florida and is a subsidiary of J&J. Cordis denies the remaining allegations in Paragraph 5.

COMPLAINT 6. This action arises under the Patent Laws of the United States (35 U.S.C. § 1, *et seq.*).

ANSWER 6. Cordis admits that this action seeks a declaratory judgment of invalidity and infringement and thus implicates the patent laws of the United States. Cordis denies the remaining allegations in Paragraph 6.

COMPLAINT 7. This Court has jurisdiction over the subject matter of all causes of action herein pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201 and 2202.

ANSWER 7. Cordis admits that the Court determined in an opinion dated January 25, 2008 that subject matter jurisdiction exists for this action. Cordis denies the remaining allegations in Paragraph 7.

COMPLAINT 8. On information and belief, J&J has systematic and continuous contacts in this judicial district.

ANSWER 8. Cordis states that it does not contest that the Court has personal jurisdiction over Cordis in this action. Cordis denies the remaining allegations in Paragraph 8.

COMPLAINT 9. On information and belief, J&J regularly avails itself of the benefits of this judicial district, including the jurisdiction of the courts.

ANSWER 9. Cordis admits that it has, in certain instances, availed itself of the benefits of this judicial district, and, in certain instances, this included the jurisdiction of the courts. Cordis denies the remaining allegations in Paragraph 9.

COMPLAINT 10. On information and belief, J&J regularly transacts business within this judicial district.

ANSWER 10. Cordis admits that it transacts business within this judicial district. Cordis denies the remaining allegations in Paragraph 10.

COMPLAINT 11. On information and belief, J&J regularly sells products in this judicial district. J&J derives substantial revenues from sales in this district.

ANSWER 11. Cordis admits that it sells products in this judicial district. Cordis further admits that it derives revenues from sales of products in this district. Cordis denies the remaining allegations in Paragraph 11.

COMPLAINT 12. This Court has personal jurisdiction, general and specific, over J&J.

ANSWER. Cordis states that it does not contest personal jurisdiction in this action. Cordis denies the remaining allegations in Paragraph 12.

COMPLAINT 13. Venue in this judicial district is proper pursuant to 28 U.S.C. §§ 1391(b) and (c) and 1400(b).

ANSWER. Cordis states that it does not contest that venue exists for this action in this judicial district. Cordis denies that this judicial district is the appropriate or most convenient forum in which to litigate this action. Cordis believes that the appropriate forum

to litigate this action is the District of New Jersey, where earlier-filed cases are pending involving the exact same patents and the exact same accused product as in this action.

COMPLAINT 14. BSC is a world renowned leader in the development of intravascular stents used to treat coronary artery disease.

ANSWER. Cordis admits that Boston Scientific develops, manufactures and sells stent delivery systems throughout the world and that these products are used to treat coronary artery disease. Cordis denies the remaining allegations in Paragraph 14.

COMPLAINT 15. J&J and, in particular, Cordis, directly compete with BSC in the field of intravascular stents used to treat coronary artery disease.

ANSWER. Cordis admits that Cordis directly competes with BSC in the field of intravascular stents used to treat coronary artery disease. Cordis denies the remaining allegations in Paragraph 15.

COMPLAINT 16. J&J has a well-known history of suing competitors, including BSC, in the field of intravascular stents for patent infringement. Within the past several years, J&J and/or Cordis have sued BSC in this Court, alleging patent infringement in cases involving intravascular stents used to treat coronary artery disease. BSC has also brought suits for patent infringement against J&J within this judicial district.

ANSWER. Cordis admits that there has been litigation in the stent industry, that Cordis has, in the past, brought actions in this Court against Boston Scientific for infringement of patents relating to intravascular stents used to treat coronary artery disease, and that Cordis's stent patents have been found after jury trials to be valid and infringed by BSC. Cordis admits that Boston Scientific has, in the past, sued Cordis for patent infringement in this Court. Cordis denies the remaining allegations in Paragraph 16.

COMPLAINT 17. Pursuant to an agreement between BSC and Abbott Laboratories ("Abbott"), BSC is presently selling the PROMUS™ Stent System ("PROMUS") in Europe. The PROMUS stent is a private-labeled XienceV™ Everolimus-Eluting Coronary Stent System ("XIENCE V") which is manufactured for BSC by Abbott in the United States. The PROMUS stent is an intravascular stent used to treat coronary artery disease. It advantageously releases a drug designed to diminish reblocking (restenosis) of the patient's blood vessel into which the stent has been inserted.

ANSWER. Cordis admits that BSC has stated that pursuant to an agreement between it and Abbott, BSC has rights to sell the Promus coronary stent. Cordis further admits that BSC has stated that the Promus stent is a private-labeled Xience V stent manufactured for BSC by Abbott in the United States. Cordis admits that BSC is presently selling the Promus stent in Europe and other countries outside the United States. Cordis further admits that the Promus stent is an intravascular stent used to treat coronary artery disease, and releases the drug Everolimus, a macrocyclic lactone analog of rapamycin, which is designed to diminish restenosis of the patient's blood vessel into which the stent has been inserted. Cordis is without knowledge or information sufficient to form a belief as to the truth of the remaining allegations in Paragraph 17, and therefore denies the same.

COMPLAINT 18. The PROMUS stent received CE Mark approval in October 2006, which allows BSC to distribute PROMUS in 27 countries of the European Economic Area. Since that time, BSC has been taking title to the PROMUS stent from Abbott in the United States and then exporting those stents to the European market. BSC intends to begin selling its PROMUS stent in the United States in 2008; FDA approval is pending.

ANSWER. Cordis admits that the Promus stent received CE Mark approval in October 2006, which allows Boston Scientific to distribute the Promus stent in Europe. Cordis is without knowledge or information sufficient to form a belief as to the truth of the remaining allegations in Paragraph 18.

COMPLAINT 19. In 2006, BSC purchased Guidant Corporation ("Guidant"). As part of the agreement governing the Guidant acquisition, Guidant separately sold the rights to its everolimus-eluting stent product to Abbott. BSC separately entered into an agreement with Abbott that permits BSC to sell (under the designation "PROMUS") the everolimus-eluting stents manufactured by Abbott (which Abbott sells on its own as its "XIENCE V" stent).

ANSWER. Cordis admits that on January 25, 2006, Guidant and Boston Scientific announced that they had entered into a merger agreement, and Guidant announced that Abbott would acquire Guidant's intervention and endovascular businesses. Cordis admits

that BSC has stated that, pursuant to an agreement between it and Abbott, BSC is presently selling the Promus coronary stent, and that the Promus stent is a private-labeled XienceV stent manufactured for BSC by Abbott in the United States. Cordis is without knowledge or information sufficient to form a belief as to the truth of the remaining allegations in Paragraph 19.

COMPLAINT 20. Abbott currently manufactures and sells its own everolimus-eluting stent, the XIENCE V stent, which is the same product as BSC's PROMUS stent.

ANSWER. Cordis admits that Abbott is currently manufacturing and selling the Xience V stent. Cordis further admits that BSC has stated that the Promus stent is a private-labeled version of the Xience V stent. Cordis is without knowledge or information sufficient to form a belief as to the truth of the remaining allegations in Paragraph 20.

COMPLAINT 21. On May 15, 2007, Cordis Corporation filed a patent infringement suit against Abbott in the United States District Court for the District of New Jersey. *See* Exhibit B, the Complaint in Civil Action No. 07-2265-JAP-TJB. Cordis alleges in its May 15 Complaint that Abbott's manufacture and/or use of the XIENCE V stent in the United States infringes the Falotico '286 patent. *Id.*, pp. 3-4. Among other remedies, Cordis seeks a preliminary and permanent injunction prohibiting Abbott from making, using, selling, or offering for sale the XIENCE V stent in the United States. *Id.*, p. 4.

ANSWER. Cordis admits the allegations in Paragraph 21.

COMPLAINT 22. Cordis' patent infringement suit, as referenced in paragraph 21, has created a present substantial controversy between J&J and BSC concerning the PROMUS stent. J&J, through Cordis, has asserted rights under the Falotico '286 patent against the same product as the PROMUS stent, and the alleged infringement of that patent has created apprehension that, if Cordis is successful in its suit, BSC's investment in the PROMUS stent will be harmed.

ANSWER. Cordis admits that the Xience V stent infringes the Falotico '286 patent, and that it has asserted infringement of the Falotico '286 patent against the Xience V stent. Cordis denies the remaining allegations in Paragraph 22.

COMPLAINT 23. On May 15, 2007, prior to the filing of Cordis' patent infringement case against Abbott in the District of New Jersey, Abbott filed a declaratory judgment action against Cordis in the United States District Court for the District of

Delaware. *See* Exhibit C, the complaint in Civil Action No. 07-259-SLR. Abbott alleges in its May 15 Complaint that the Falotico ‘286 patent is invalid and not infringed by Abbott’s manufacture and/or use of the XIENCE V stent in the United States. *Id.*, p. 17.

ANSWER. Cordis admits that Abbott filed a declaratory judgment action against Cordis in the United States District Court for the District of Delaware on May 15, 2007, that this action was assigned Civil Action No. 07-259-SLR (“the ‘259 action”), and that Abbott claimed in that action that Cordis’s U.S. Patent No. 7,217,286 was invalid and not infringed by its XIENCE V stent. Cordis further states that on May 15, 2007, prior to Abbott filing the ‘259 action in Delaware, Cordis Corp. filed a parallel patent infringement action against Abbott on the same patent in the United States District Court for the District of New Jersey. That case is captioned Cordis Corp. v. Abbott Laboratories, Civil Action No. 07-2265-JAP (“the ‘2265 action”). Cordis further states that on November 28, 2007, the United States District Court for the District of Delaware dismissed the ‘259 action in favor of the parallel first filed action by Cordis against Abbott in the District of New Jersey and denied Abbott’s motion to enjoin Cordis from prosecuting the ‘2265 action in the District of New Jersey. Cordis denies the remaining allegations in Paragraph 23.

COMPLAINT 24. Abbott’s declaratory judgment action against the Falotico ‘286 patent is currently pending in this judicial district is the first filed action concerning the ‘286 patent. The instant action by BSC against J&J is related to Abbott’s May 15 action in terms of the ‘286 patent at issue, the prior art to that patent, and the nature of the products of the declaratory judgment defendants, XIENCE V (Abbott) and PROMUS (BSC).

ANSWER. Cordis denies that the ‘259 action is currently pending in this judicial district and denies that it was the first filed action concerning the ‘286 patent. Cordis states that, on May 15, 2007, prior to Abbott filing the ‘259 action in Delaware, Cordis Corp. filed a parallel patent infringement action, the ‘2265 action, against Abbott on the same patent in the United States District Court for the District of New Jersey. Cordis further states that on November 28, 2007, the United States District Court for the District of Delaware dismissed

the '259 action in favor of the parallel first filed action by Cordis against Abbott in the District of New Jersey and denied Abbott's motion to enjoin Cordis from prosecuting the '2265 action in the District of New Jersey. Cordis admits that the instant action is related to the actions brought by Cordis against Abbott and Boston Scientific in the District of New Jersey and the other actions brought by Boston Scientific against Cordis in the District of Delaware because they involve the same patent, patents in the same patent family and/or the same accused product. Cordis denies the remaining allegations in Paragraph 24.

COMPLAINT 25. Abbott has also filed, on September 29, 2006, in this Court, a declaratory judgment action against J&J, alleging that other Cordis-owned patents - U.S. Patent Nos. 6,585,764, 6,776,796, and 6,808,536 - are invalid and not infringed by Abbott's manufacture and/or use of the XIENCE V stent in the United States. *See* Exhibit D, the complaint in Civil Action No. 06-613-SLR. The '764 and '536 patents are directly related to the Falotico '286 patent. Abbott has also recently filed a motion to amend its Complaint in that action to include the Falotico '286 patent, or in the alternative, consolidate its two filed actions.

ANSWER. Cordis admits that Abbott filed a declaratory judgment action against Cordis in the United States District Court for the District of Delaware on September 29, 2006, that this action was assigned Civil Action No. 06-613-SLR ("the '613 action"), and that Abbott claimed in that action that Cordis's U.S. Patent No. 6,585,764, U.S. Patent No. 6,808,536, and U.S. Patent No. 6,776,796 were invalid and not infringed by Abbott's XIENCE V stent. Cordis further admits that on May 15, 2007, Abbott sought leave to file a supplemental complaint in the '613 action to add a declaratory judgment claim that Cordis's U.S. Patent No. 7,217,286 was invalid and not infringed by its XIENCE V stent. Cordis further states that on November 28, 2007, the United States District Court for the District of Delaware dismissed the Abbott '613 action for lack of subject matter jurisdiction, denied Abbott's motion to amend its '613 action, and denied Abbott's motion to enjoin Cordis from

prosecuting its actions against Abbott in the District of New Jersey. Cordis denies the remaining allegations in Paragraph 25.

COMPLAINT 26. BSC repeats and realleges each and every allegation contained in paragraphs 1-25 of this Complaint as though fully set forth herein.

ANSWER. Cordis incorporates and realleges its answers to Paragraphs 1-25 of the Complaint.

COMPLAINT 27. Each of the claims in the Falotico '286 patent is invalid for failure to comply with one or more of the requirements of Title 35, United States Code, including, but not limited to, 35 U.S.C. §§ 102, 103 and 112.

ANSWER. Cordis denies the allegations in Paragraph 27.

COMPLAINT 28. The PROMUS stent does not infringe any valid claim of the Falotico '286 patent.

ANSWER. Cordis denies the allegations in Paragraph 28.

COUNTERCLAIMS

For its counterclaims, Cordis alleges the following:

THE PARTIES

1. Counterclaim Plaintiff Cordis Corporation ("Cordis"), 33 Technology Drive, Warren, New Jersey, is a Florida corporation with a principal place of business in Warren, New Jersey. Cordis also has facilities in Clark, New Jersey. Cordis is a pioneer in developing invasive treatments for vascular disease, including the CYPHER[®] drug-eluting stent, a drug/device combination for the treatment of coronary artery disease.

2. Upon information and belief, Counterclaim Defendant Boston Scientific Corporation, One Boston Scientific Place, Natick, Massachusetts 01760, is a Delaware corporation with a principal place of business in Massachusetts. Upon information and belief, Counterclaim Defendant Boston Scientific Scimed, Inc. is a corporation organized under the laws of Minnesota and has a principal place of business at One Scimed

Place, Maple Grove, Minnesota 55311. Upon information and belief, Boston Scientific Scimed, Inc. is a subsidiary of Boston Scientific Corporation. Boston Scientific Corporation and Boston Scientific Scimed, Inc. will be collectively referred to herein as “BSC.”

JURISDICTION AND VENUE

3. For purposes of Cordis’s counterclaims, this Court has subject matter jurisdiction over Cordis’s patent infringement claims under 28 U.S.C. §§ 1331 and 1338(a), 2201 and 2202.

4. For purposes of Cordis Corp.’s counterclaims, venue is proper in this District under 28 U.S.C. §§ 1391(b) and (c) and 1400(b).

FACTUAL ALLEGATIONS

5. Pursuant to an agreement between BSC and Abbott Laboratories (“Abbott”), BSC is presently selling the Promus drug-eluting coronary stent in Europe and other countries outside the United States. The Promus stent is a private-labeled version of the Abbott Xience V drug-eluting stent which is manufactured for BSC by Abbott in the United States.

6. The Promus stent received CE Mark approval in October 2006, which allows BSC to distribute the Promus stent in Europe. Since that time, on information and belief, BSC has been taking title to the Promus stent from Abbott in the United States and exporting those stents to the European market.

7. BSC has previously stated that it intends to begin selling its Promus stent in the United States in 2008. On November 29, 2007, a committee of advisors to the FDA voted to recommend approval of the Abbott Xience V stent, which is the same stent as the Promus stent. BSC has stated that it believes that FDA approval of the Promus stent is

imminent, and that it intends to begin selling the Promus stent in the United States upon FDA approval.

8. On May 29, 2007, the United States Patent and Trademark Office duly and legally issued United States Patent No. 7,217,286 entitled “Local Delivery of Rapamycin for Treatment of Proliferative Sequelae Associated With PTCA Procedures, Including Delivery Using a Modified Stent” (“the Falotico ‘286 patent”) The Falotico ‘286 patent issued to Wright et al. Cordis is the owner of the Falotico ‘286 patent.

9. Upon sale of the Promus stent in the United States, BSC will be infringing the Falotico ‘286 patent, including but not limited to selling the Promus stent in the United States for use by physicians in coronary angioplasty procedures.

10. Upon the launch of the Promus stent in the United States, the Promus stent will compete directly with Cordis’s CYPHER stent, reducing Cordis’s market share and causing irreparable harm to Cordis.

11. BSC’s announced intention to sell the Promus stent upon FDA approval has created a present actual and substantial controversy between Cordis and BSC concerning the threatened infringement of the Falotico ‘286 patent.

COUNT I: INFRINGEMENT OF THE ‘286 PATENT

12. Cordis realleges paragraphs 1-11 above as if fully set forth herein.

13. Upon offer for sale and sale of the Promus stent in the United States, BSC will be directly infringing, contributorily infringing, and/or inducing infringement of the Falotico ‘286 patent in violation of 35 U.S.C. § 271, by, including but not limited to, selling and offering for sale the Promus stent in the United States for use by physicians in coronary angioplasty procedures.

14. BSC has engaged in concrete steps taken with the intent to conduct infringing activity. An actual and justiciable controversy exists between Cordis and BSC regarding infringement of the Falotico '286 patent.

15. BSC had and has actual notice of the Falotico '286 patent. Upon offer for sale and sale of the Promus stent in the United States, BSC will be infringing the Falotico '286 patent with knowledge of Cordis's patent rights. BSC's actions are willful and deliberate.

PRAYER FOR RELIEF

WHEREFORE, Cordis prays that the Court enter judgment as follows:

1. For a declaratory judgment in favor of Cordis that BSC is directly infringing, contributorily infringing, and/or inducing infringement of the Falotico '286 patent;
2. For a declaratory judgment in favor of Cordis that the Falotico '286 patent is not invalid;
3. For an injunction pursuant to 35 U.S.C. § 283 prohibiting BSC from making, using, selling, importing, or offering for sale the Promus stent in the United States;
4. For a determination that this is an exceptional case within the meaning of 35 U.S.C. § 285, and an award to Cordis of its reasonable attorneys' fees; and
5. For such other and further relief in law or in equity to which Cordis may be justly entitled.

ASHBY & GEDDES

/s/ Steven J. Balick

Steven J. Balick (I.D. #2114)
John G Day (I.D. #2403)
Lauren E. Maguire (I.D. #4261)
500 Delaware Aveune, 8th Floor
P.O. Box 1150
Wilmington, Delaware 19899
302-654-1888
sbalick@ashby-geddes.com
jday@ashby-geddes.com
lmaguire@ashby-geddes.com

*Attorneys for Johnson & Johnson, Inc. and
Cordis Corporation*

Of Counsel:

David T. Pritikin
William H. Baumgartner, Jr.
Russell E. Cass
SIDLEY AUSTIN LLP
One South Dearborn
Chicago, Illinois 60603
Telephone: (312) 853-7000
Facsimile: (312) 853-7036

Dated: February 21, 2008
188457.1